CYB001 tolerability in healthy participants

CYB001 is a psilocybin formulation designed to treat major depressive disorder (MDD). CYB001 has been developed by Cybin.

Cybin has received approval from the Institutional Review Board (IRB) at the University of the West Indies Hospital in Jamaica for a Phase II trial using CYB001.

This Phase II trial will assess Cybin’s sublingual psilocybin formulation versus a 25mg psilocybin capsule. A Phase IIa study will enrol 40 patients to determine the bio-equivalent dose of CYB001 when compared to a 25mg capsule.

Topic Healthy Subjects Depression
Compound Psilocybin Placebo
Country Jamaica Canada
Visit trial
Status Planned
Results Published
Start date 31 December 2021
End date 31 December 2022
Chance of happening 89%
Phase Phase II
Design Open
Type Interventional
Generation Second
Participants 40
Sex All
Age 18- 99
Therapy No

Trial Details



NCT Number

Sponsors & Collaborators

Cybin
Cybin is a for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021). It has raised $98 million US.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.